Fresenius SE & Co. (OTCMKTS:FSNUY) Sees Significant Decrease in Short Interest

Fresenius SE & Co. (OTCMKTS:FSNUY) was the target of a large decline in short interest in September. As of September 30th, there was short interest totaling 28,906 shares, a decline of 51.7% from the September 15th total of 59,859 shares. Based on an average daily trading volume, of 160,909 shares, the short-interest ratio is presently 0.2 days. Approximately 0.0% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Morgan Stanley reissued an “overweight” rating on shares of Fresenius SE & Co. in a report on Tuesday, July 21st. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Fresenius SE & Co. in a research report on Thursday, August 6th. Three research analysts have rated the stock with a Buy rating. According to data from MarketBeat.com, the stock presently has an average rating of “Buy”.

Fresenius SE & Co. Price Performance

FSNUY traded up $0.25 during midday trading on Wednesday, hitting $12.33. The stock had a trading volume of 243,973 shares, compared to its average volume of 163,425. The company has a market cap of $27.78 billion, a P/E ratio of 15.61 and a beta of 0.60. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.97 and a current ratio of 1.28. The business has a fifty day moving average of $13.09 and a 200 day moving average of $12.35. Fresenius SE & Co. has a 1 year low of $10.33 and a 1 year high of $33.93.

Fresenius SE & Co. (OTCMKTS:FSNUY) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.01). The company had revenue of $6.91 billion during the quarter, compared to analysts’ expectations of $6.65 billion. Fresenius SE & Co. had a return on equity of 10.25% and a net margin of 6.67%. As a group, equities analysts forecast that Fresenius SE & Co. will post 1.08 earnings per share for the current fiscal year.

Fresenius SE & Co. Company Profile

Fresenius SE & Co KGaA is a German healthcare company headquartered in Bad Homburg, Germany. The group develops and provides products and services for hospitals, outpatient care providers and patients, with operations focused primarily on healthcare products and hospital services.

Its Fresenius Kabi business supplies medicines and technologies used in infusion therapy, clinical nutrition and transfusion medicine. Its portfolio includes intravenous drugs, generic medicines, biosimilars, infusion systems, medical devices and products for parenteral and enteral nutrition.

Fresenius also operates hospitals through Helios, which manages acute-care and rehabilitation facilities in Germany and hospitals and other healthcare services in Spain through the Quirónsalud network.